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Mesenchymal stromal cells (MSCs) hold great promise for 
regenerative medicine. Stable ex vivo gene transfer to MSCs 
could improve the outcome and scope of MSC therapy, 
but current vectors require multiple rounds of transduc-
tion, involve genotoxic viral promoters and/or the addition 
of cytotoxic cationic polymers in order to achieve efficient 
transduction. We describe a self-inactivating foamy virus 
vector (FVV), incorporating the simian macaque foamy 
virus envelope and using physiological promoters, which 
efficiently transduces murine MSCs (mMSCs) in a single-
round. High and sustained expression of the transgene, 
whether GFP or the lysosomal enzyme, arylsulphatase 
A (ARSA), was achieved. Defining MSC characteristics 
 (surface marker expression and differentiation potential), 
as well as long-term engraftment and distribution in the 
murine brain following intracerebroventricular delivery, 
are unaffected by FVV transduction. Similarly, greater than 
95% of human MSCs (hMSCs) were stably transduced 
using the same vector, facilitating human application. This 
work describes the best stable gene transfer vector avail-
able for mMSCs and hMSCs.
Received 11 February 2016; accepted 19 April 2016; advance online  
publication 7 June 2016. doi:10.1038/mt.2016.91
INTRODUCTION
Mesenchymal stromal cells (MSCs) are a heterogeneous popula-
tion of adult cells of mesodermal origin that can be readily isolated 
from bone marrow or adipose tissue and efficiently expanded 
in vitro as plastic-adherent cells. They contain a proportion of 
cells capable of differentiating into osteocytes, adipocytes, and 
chondrocytes under appropriate conditions.1 MSCs have been 
extensively tested in a number of clinical conditions and proved 
enormous potential.2 In vivo, tissue-resident MSCs are thought to 
be recruited to sites of inflammation where they play a regula-
tory role in wound-healing, immune modulation, angiogenesis, 
and tissue homeostasis.3,4 Inflammation-directed trafficking may 
still be retained by exogenously administered MSCs, thus making 
the case for their use as cancer-targeting cells5,6 and site-directed 
immunosuppressive and pro-repair effector cells,7 the latter being 
extensively exploited for a wide-range of diseases, such as rheu-
matoid arthritis, type-1 diabetes, and neurological diseases such 
as amyotrophic lateral sclerosis and stroke.8,9
Long-term engraftment of MSCs in the central nervous system 
(CNS)10,11 facilitates their use as cellular vectors for neurodegenera-
tive diseases, including Huntington’s disease,12 Parkinson’s disease,13 
and lysosomal storage diseases,14 which are caused by a lysosomal 
enzyme deficiency. Lysosomal enzymes are tagged with a mannose-
6-phosphate to enable their retrieval from the secretory pathway by 
its binding to the mannose-6-phosphate receptor.15 This retrieval is 
leaky, resulting in some secretion of lysosomal enzyme.16 Secreted 
enzyme is then retrieved by mannose-6-phosphate receptor at the 
cell-surface. This secrete-and-recapture system can be exploited 
in gene and cell therapies since enzyme expression in one cell can 
correct many others. For example, metachromatic leukodystrophy 
(MLD), one of the most common lysosomal storage diseases, is 
caused by a deficiency of arylsulphatase A (ARSA) causing storage of 
sulphatide in oligodendrocytes, Schwann cells, and neurons leading 
to progressive demyelination and, in its most common form, death 
by 5 years of age.17 Overexpression of ARSA in hematopoietic stem 
cells can reduce sulphatide storage caused by ARSA deficiency in the 
CNS of mice,18 despite efficacy being dependent on the recruitment 
of microglia across the blood-brain-barrier. This demonstrates that 
relatively few cells expressing ARSA could be sufficient to prevent 
disease. Since MSCs can be safely delivered to humans, intrave-
nously19 and directly to the brain,20–22 a gene and MSC therapy could 
complement or exceed a hematopoietic stem cell-based approach.
Any vector for gene transfer to MSCs should persist during 
cell division to allow ex vivo expansion. Vectors based on retro-
viruses, which integrate the vector DNA into the host genome 
readily achieve this. However, retroviral gene therapy trials have 
proven that these vectors carry a significant risk23,24 due to geno-
toxicity that is linked to the vectors’ integration sites, the presence 
of strong viral enhancers and/or transcriptional read-through.25–28 
Consequently, modern clinically relevant gene therapy vectors 
are deleted of promoter/enhancer activity from the viral long ter-
minal repeats (LTRs) (termed self-inactivating (SIN) vectors29) 
and employ nonviral physiological promoters to drive transgene 
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expression.30 Nonetheless, the commonly used integrating vectors 
(γ-retroviral or lentiviral) have so far failed to transduce MSCs 
efficiently while retaining the aforementioned safety features.31 
Thus, a SIN vector with a physiological promoter that can effi-
ciently transduce rodent and hMSCs would boost combined gene 
and MSC therapies.
Foamy viruses are nonhuman, apathogenic viruses that form 
a distinct subgroup of the Retroviridae.32,33 Self-inactivating foamy 
virus vectors (FVV) based on the prototype foamy virus (PFV) are 
well characterized34–38 and effective in large animal models of dis-
ease.39,40 An historical disadvantage of FVVs is that they induced a 
marked cytopathic effect (CPE) at a high multiplicity of infection 
(MOI) in vitro due to the fusogenic nature of the PFV envelope 
(Env).32 The simian macaque foamy virus envelope (SFVmac Env) 
has recently been shown to be less fusogenic than that of PFV,41 
but has not been described in gene transfer.
This paper describes optimization of FVVs for high transduc-
tion efficiency and transgene expression in mMSCs and hMSCs. 
By employing the SFVmac Env, high transduction efficiencies 
(>95%) in MSCs are achieved from a single-round of transduction 
by FVV containing the cellular phosphoglycerate kinase (PGK) 
promoter. Viral promoters or toxic chemicals are not involved 
and transgene expression is high and stable for at least 10 passages 
post-transduction. MSC differentiation potential and surface 
marker expression is preserved after FVV transduction at high 
MOI, as is the distribution and long-term engraftment of mMSCs 
delivered directly to the murine brain. Thus, we describe the best 
existing vector for stable MSC gene transfer.
RESULTS
The PFV Env induces syncytia formation in target cells at high 
MOI. Since the less fusogenic SFVmac Env has not yet been tested 
in gene transfer, we compared the transduction efficiency in 
mMSCs of FVV with either the PFV or SFVmac Env at different 
MOIs and assessed the CPE microscopically. Aside from the 
alternative envelopes, both vectors were identical, each carrying 
the same PGK-GFP construct (all FVV constructs are shown in 
Figure 1). Both envelopes produced good vector titers, typically 
ranging between 108 and 109 HT1080 transducing units per ml 
after 100-fold concentration. Transduction efficiency was deter-
mined by flow cytometry as the percent of GFP expressing mMSCs 
following a single passage post-transduction (Figure 2a). At low 
MOIs of 1 and 5, the transduction efficiency for FVV with either 
the PFV or SFVmac Env was similar. At higher MOIs of 10 or more, 
the FVV with SFVmac Env resulted in significantly higher trans-
duction efficiency than with PFV Env. This difference correlated 
with the MOI at which PFV Env induced extensive CPE, although 
syncytia formed at all MOIs tested using this envelope. In com-
parison, no CPE was observed even at the highest MOI of 50 for 
FVV with SFVmac Env. The highest transduction efficiency by FVV 
with PFV Env was achieved between MOIs of 30 and 50 with 72 
and 74% GFP-expressing cells, respectively, but was accompa-
nied by a marked CPE. At the same MOIs, FVV with SFVmac Env 
achieved 92 and 95% transduction efficiency, respectively, with no 
CPE. Representative photomicrographs of mMSCs transduced at 
MOI 30 with each vector are shown in Figure 2b,c, demonstrat-
ing the widespread syncytia induced only by PFV Env 20 hours 
after vector addition. All subsequent experiments employed FVV 
enveloped with SFVmac Env.
The PGK and elongation factor 1α short (EFS) promoters are 
constitutive cellular promoters that, in contrast to viral promoters, 
have performed well in sensitive genotoxicity assays that measure 
neighboring gene activation.30 The ability of these promoters to 
achieve high transduction efficiency and maintain expression of 
GFP in FVV transduced mMSCs through cell expansion, a pre-
requisite for cell therapy manufacturing, was compared. Vectors 
FVV:PGK-GFP and FVV:EFS-GFP (Figure  1), were used to 
transduce mMSCs at MOIs of 1, 30, and 50. Transduced mMSCs 
were analyzed by flow cytometry to determine the percent of GFP 
expressing cells (Figure 3a) and their median fluorescence inten-
sity (MFI) (Figure  3b) after each passage post-transduction up 
to the 10th passage (cells were passaged once confluence reached 
over 90% by reseeding one-tenth of the cells). This represents con-
tinuous culture over a period of 6 weeks. Representative photomi-
crographs of GFP fluorescence from MOI 30 transduced mMSCs 
is shown in Figure  3c,d. Since a MOI of 50 produced similar 
results to a MOI of 30 for both constructs at all passages, for clar-
ity only data derived from a MOI of 30 are shown (Figure 3).
At a MOI of both 1 and 30, FVV:PGK-GFP transduction results 
in a higher percentage of mMSCs expressing GFP than FVV:EFS-
GFP (Figure 3a). Over 96% of mMSCs expressed GFP from two 
passages post-transduction with FVV:PGK-GFP and was sus-
tained through subsequent passages. Comparatively, transduction 
with FVV:EFS-GFP at a MOI of 30 (or 50) only resulted in ~75% 
of mMSCs expressing GFP. At the low MOI of 1, most transduced 
cells contain a single vector copy (compared to multiple copies 
at high MOI), allowing for better analysis of expression persis-
tence postexpansion. At this MOI, transduction with FVV:PGK-
GFP enabled GFP expression in ~45% of mMSCs, stable over the 
10 passages. Conversely, the 40% of mMSCs expressing GFP at 
1 passage post-transduction with FVV:EFS-GFP reduced to less 
than 15% by passage 4 post-transduction. Both EFS and PGK offer 
stable expression levels in the mMSCs that continue to express 
GFP, since the MFI does not change after repeated passaging 
(Figure  3b). The PGK promoter drives approximately fivefold 
higher GFP expression levels than EFS when mMSCs are trans-
duced at a MOI of 30 from the second passage post-transduc-
tion, whereas the promoters performed similarly at one passage 
Figure 1 Schematic of foamy virus vectors (FVVs) used in this study. 
All FVVs contain self-inactivating long-terminal repeats (SIN-LTR, black 
boxes) with the U3 region deleted of promoter and enhancer activity. 
The cis-acting sequences I and II (CASI/II) are viral sequences necessary 
for virion assembly. Promoter and transgene of choice are inserted in 
a multiple cloning site (large white box). A postregulatory element is 
included in all constructs to improve transgene expression. ARSA, aryl-
sulphatase A (codon optimized for human expression); EFS, elongation 
factor 1α short (intron-less version); GFP, enhanced green fluorescent 
protein; PGK, murine phosphoglycerate kinase promoter.
SIN-LTR SIN-LTRPGK-GFPCASI/II PRE
SIN-LTR SIN-LTREFS-ARSACASI/II PRE
SIN-LTR SIN-LTRPGK-ARSACASI/II PRE
SIN-LTR SIN-LTREFS-GFPCASI/II PRE
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Figure 2 Effect of foamy virus vector (FVV) envelope on mMSC transduction efficiency and cytopathic effect. (a) The percent of GFP express-
ing mMSCs after 1 passage post-transduction with PGK-GFP enveloped with PFV Env (brick patterned) or SFVmac Env (white) at different multiplicity 
of infection (MOIs) was determined by flow cytometry. The mean + SD of biological triplicates is shown. Significant differences between means at 
each MOI are indicated by asterisks according to the P value as determined by two-way analysis of variance with Bonferroni’s multiple comparisons 
test. (b,c) Photomicrographs of MSCs 20 hours after vector addition. Scale bar = 50 µm. (b) Transduced at MOI 30 using PFV Env; (c) Transduced 
at MOI 30 using SFVmac Env.
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Figure 3 Comparison of the PGK and EFS promoter for sustained GFP expression in mMSCs. (a) The percentage of mMSCs expressing GFP and 
(b) their median fluorescence intensity following transduction at multiplicity of infection (MOI) 1 (squares) or MOI 30 (triangles) using FVV:PGK-GFP 
(white) or FVV:EFS-GFP (black). Flow cytometry analysis was performed when cells reached ~90% confluence at 1 to 10 passages post-transduction. 
For each passage, 1/10th of the total cells were reseeded. Data points show the mean + SD of data from biological triplicates. Asterisks mark values 
that are significantly different from the previous passage of the same sample, as determined by two-way analysis of variance with Bonferroni multiple 
comparisons tests. (c,d) Representative photomicrographs of GFP fluorescence in mMSCs transduced at a MOI of 30 with PGK-GFP (c) or EFS-GFP 
(d), taken three passages post-transduction. FVV, foamy virus vector.
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post-transduction. Together, Figure 3a,b demonstrates the supe-
riority of PGK as a promoter compared to EFS for FVV-mediated 
expression of GFP in mMSCs, providing higher expression levels, 
higher transduction rates, and long-term stability.
A codon-optimized arylsulphatase A (ARSA) open reading 
frame replaced GFP in our FVVs to produce FVV:PGK-ARSA 
and FVV:EFS-ARSA (Figure 1). For high transduction efficiency, 
mMSCs were transduced at a MOI of 30 with these FVVs and the 
transduced cells collected after 1 passage. One-tenth of the cells 
were reseeded until the 5th passage post-transduction. The remain-
ing cells were lysed to determine the intracellular ARSA activity 
by the ARSA assay42 (Figure 4a). Low basal activity was detected 
by mMSCs transduced with FVV:PGK-GFP (control lysate). Both 
FVV:PGK-ARSA and FVV:EFS-ARSA induced strong ARSA 
activity, the highest being at passage 2 post-transduction from both 
vectors. The PGK promoter resulted in a twofold higher enzyme 
activity at this passage. The ARSA activity remained stable over 
subsequent passages for FVV:PGK-ARSA-transduced mMSCs, 
whereas the activity in FVV:EFS-ARSA transduced mMSCs 
reduced between each passage with a statistically significant reduc-
tion between passages 4 and 5 post-transduction. These data are in 
line with those generated for GFP expression.
Since any MSC-based therapy for a lysosomal storage dis-
ease would depend on sufficient enzyme secretion and its correct 
processing with a mannose-6-phosphate to allow its recapture 
by endogenous cells, the ARSA activity in mMSC cell-culture 
medium and its ability to be taken up and used by MLD patients’ 
fibroblasts was determined. The control cell-culture medium from 
mMSCs transduced with FVV:PGK-GFP had a low ARSA activity 
(hydrolysing 3.3 nmol of substrate per hour per ml) (Figure 4b), 
whereas FVV:PGK-ARSA-transduced mMSCs hydrolyzed over 
80 nmol of substrate per hour per ml, which was twofold higher 
than FVV:EFS-ARSA transduced mMSCs. Next, the FVV:PGK-
ARSA transduced mMSCs cell-culture medium, or that from 
FVV:PGK-GFP (control medium), was incubated with normal 
(functional ARSA) or MLD patients’ (ARSA deficient) fibro-
blasts that had been preloaded with fluorescently labelled sub-
strate (BODIPY-sulphatide). Media from both cultures were 
prediluted to the same extent, such that 0.5 units of ARSA (the 
amount needed to process 0.5 pmol of substrate per hour in 
the ARSA assay) was added to fibroblasts in the FVV:PGK- 
ARSA-transduced mMSC medium. This dilution caused the con-
tribution of endogenous ARSA to be negligible. Fibroblasts from 
normal donors stored only low amounts of BODIPY-sulphatide 
in the presence of control or FVV:PGK-ARSA-transduced mMSC 
medium, as expected (Figure 4c). Comparatively, fibroblasts from 
both MLD patients stored BODIPY-sulphatide in the presence 
of control medium. Storage was reduced when medium from 
FVV:PGK-ARSA-transduced mMSCs was added, demonstrating 
that FVV:PGK-ARSA-encoded ARSA is correctly processed by 
transduced mMSCs and can correct enzyme-deficient cells.
The effects of FVV transduction on mMSC identity and func-
tion were examined by comparing untransduced mMSCs and 
mMSCs transduced at MOI 30 with FVV:PGK-GFP or FVV:PGK-
ARSA. A panel of antibodies targeting surface markers known to 
be expressed or not in mMSCs was employed and staining assessed 
by flow cytometry. Transduced and untransduced mMSCs stained 
correctly for all markers with no discernible difference in stain-
ing intensity when quantified using the Flowjo Chi squared com-
parison (Figure  5a,b). Similarly, transduced mMSCs were able 
to differentiate into osteocytes, chondrocytes, and adipocytes to 
a similar extent as untransduced mMSCs when cultured under 
appropriate conditions (Figure 5c–k).
Given the prospect of using MSCs for therapy of diseases affect-
ing the CNS, a sensitive quantitative polymerase chain reaction 
Figure 4 Foamy virus vector (FVV) mediates high and sustained 
expression of ARSA in mMSCs. (a) Lysates of mMSC transduced cells 
were taken at each passage from 1 to 5 post-transduction. Lysates 
were mixed with σ-nitrocatechol sulphate in conditions that specifically 
enable hydrolysis to be catalyzed by ARSA. The nmol of substrate hydro-
lyzed per hour and per mg of total protein per ml are given as mean + 
SD of data from biological triplicates. Two-way analysis of variance with 
Bonferroni multiple comparisons tests was used to identify significant 
differences between passages of the same transduced mMSCs. Where a 
passage was identified to be significantly different from the previous pas-
sage of the same population, asterisks are shown to indicate the P value. 
(b) The cell-culture medium of mMSCs transduced with the FVV indi-
cated was collected and used in the ARSA assay. The nmol of substrate 
hydrolyzed per hour per ml of cell-culture medium is given as mean + 
SD of data from biological triplicates. (c) Human fibroblasts from two 
normal donors (N1 and N2) and two metachromatic leukodystrophy 
patients’ fibroblasts were loaded with BODIPY-sulphatide then cultured 
in the presence of dilute cell-culture medium from FVV:PGK-GFP (white) 
or FVV:PGK-ARSA (diamond patterned) transduced mMSCs. After 
24 hours, the pmol of BODIPY-sulphatide present in the samples was 
determined by HPLC analysis. Values (mean + SD of technical triplicates) 
are normalized to BODIPY-lactosylceramide which was added immedi-
ately prior to lipid extraction as a recovery standard.
100
a
b c
80
60
N1 N2 MLD1 MLD2
Patient fibroblasts
40
n
m
o
l p
-n
itr
oc
at
ec
ho
l s
ul
ph
at
e
hy
dr
ol
ys
ed
/h
ou
r/m
l c
el
l-c
ul
tu
re
 m
ed
iu
m
n
m
o
l p
-n
itr
oc
at
ec
ho
l s
ul
ph
at
e
hy
dr
ol
ys
ed
/h
ou
r/m
g/
m
l
10
8
6
4
2
0
pm
ol
 B
O
DI
PY
-s
ul
ph
at
id
e 
pe
r s
am
pl
e
20
0
PG
K-G
FP
PG
K-A
RS
A
EF
S-A
RS
A
1 2 3 4 5
Passages after transduction
PGK-GFP
PGK-ARSA
PGK-GFP
PGK-ARSA
EFS-ARSA
*
10,000
8,000
6,000
***
***
4,000
2,000
0
1230 www.moleculartherapy.org vol. 24 no. 7 jul. 2016
Official journal of the American Society of Gene & Cell Therapy
Efficient Gene Transfer to Mesenchymal Stromal Cells
(qPCR) targeting the Y-chromosome to allow detection of male 
mMSCs delivered directly to the brains of female mice43 was estab-
lished. To determine if FVV transduction affected the long-term 
engraftment capability of mMSCs, untransduced or FVV:EFS-
ARSA-transduced male mMSCs were each injected into the right lat-
eral ventricle of six female mice. Three months postinjection, treated 
mice were sacrificed and their brains crudely sectioned into eight 
blocks (Figure  6a). Genomic DNA was isolated from each block 
and the amount of male (mMSC-derived) DNA was determined 
by qPCR. The number of male genomes present per million total 
genomes (male and female) is shown for sections 1–8 in Figure 6b. 
Data points are only shown for sections that exceeded the detec-
tion limit of approximately 10 male genomes per million. Section 6, 
which includes the injected ventricle (Figure 6a), was the most likely 
section to contain detectable levels of mMSC DNA with 11 of the 
12 injected mice having detectable levels. This section also tended 
to contain a higher proportion of male DNA than other sections. 
Section 3, containing the noninjected lateral ventricle, also featured 
high levels of male DNA in most treated mice. The cerebellum (sec-
tion 8) was the least likely section to harbor mMSC DNA with only 
two mice having sufficient numbers for detection, both of which had 
been injected with FVV transduced mMSCs. Higher numbers of 
mice had detectable levels of male DNA in all other sections, show-
ing that mMSCs migrate from the injected lateral ventricle through-
out the brain. There was no discernible difference in distribution or 
level of engraftment between transduced and untransduced MSCs.
Figure 5 mMSC characteristics are not perturbed by foamy virus vector (FVV) transduction. (a) A panel of antibodies was used to test surface 
marker expression on mMSCs transduced or not with FVV. Representative plots (using mMSCs transduced with FVV:PGK-ARSA) are shown comparing 
isotype control antibody staining (blue) to staining with the antibody indicated above each plot (black). (b) The difference between isotype control 
and surface marker antibody signal intensity was quantified using the FlowJo Chi-squared T(x) comparison and plotted for untransduced MSCs 
(black), or mMSCs transduced with either FVV:PGK-GFP (white) or FVV:PGK-ARSA (diamond patterned). Higher values of T(x) show greater differ-
ence between surface marker antibody and the isotype control. (c–k) Representative photomicrographs are shown for mMSCs stained with Alizarin 
Red (c–e), Alcian Blue (f–h) or Oil Red O (i–k) without inducing differentiation (c,f,i) or after culturing in osteogenic (d,e), chondrogenic (g,h), or 
adipogenic (j,k) differentiation medium. mMSCs were untransduced or transduced with FVV-PGK-ARSA at a MOI of 30 as indicated.
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To test whether FVV-transduced mMSCs could maintain 
transgene expression in vivo, six adult mice were injected in their 
right lateral ventricle with FVV:PGK-GFP transduced mMSCs. 
Half the mice were sacrificed immediately postinjection and the 
other half after 45 days. Coronal cryosections of their brains were 
examined for direct GFP fluorescence (Figure 6c–f). Evidence of 
GFP expression was found for both time-points. The injected lat-
eral ventricle contained many GFP-expressing cells immediately 
postinjection and was enlarged, while the noninjected ventricle 
also contained some GFP-expressing cells. After 45-days, GFP-
expressing cells were found predominantly, but not exclusively, 
associated with the choroid plexus; along the needle track route 
in the parenchyma; and in the glomerular layer of the olfac-
tory bulb. This shows that the PGK promoter remains active in 
FVV-transduced mMSCs that have grafted long-term in the 
murine brain.
To determine whether a FVV-based MSC therapy could be 
translated from preclinical work in mice to clinical use in humans, 
the GFP-encoding FVVs were tested on hMSCs obtained from three 
different donors. At an early passage number (2–4), the hMSCs 
were transduced with FVV:PGK-GFP or FVV:EFS-GFP at different 
MOIs. At a MOI of 50, we also tested transduction of these vectors 
employing the PFV Env. The results (Figure 7a) show that, in con-
trast to results in mMSCs, the PFV Env achieved similar transduc-
tion efficiencies to SFVmac Env at high MOI. However, CPE was again 
induced by PFV Env, although to a lesser extent than in mMSCs 
at MOI 50 (not shown). At all MOIs and with either envelope, 
FVV:PGK-GFP and FVV:EFS-GFP perform similarly. For SFVmac 
Env containing FVVs, under 10% of hMSCs expressed GFP at MOI 
1. Each increase in MOI tested resulted in a higher percent of GFP 
expressing hMSCs. At an MOI of 100, the highest tried, approxi-
mately 95% of hMSCs expressed GFP. Normal morphology and no 
Figure 6 Foamy virus vector (FVV)-transduced mMSCs maintain their ability to graft in the brains of mice following intracerebroventricular 
delivery. (a) Sectioning of female mouse brains for qPCR analysis to determine long-term engraftment and distribution of male mMSCs 3 months 
after the direct delivery of 80,000 mMSCs into the right lateral ventricle (approximate location indicated with solid black circle). The dashed lines 
indicate the cuts made to produce eight sections (numbered). (b) qPCR analysis to quantify mMSCs in the brain sections depicted in a. Each data 
point represents a section from one mouse. White squares show the engraftment of untransduced mMSCs, whereas black diamonds show the 
engraftment of FVV transduced MSCs. Data for each group is from six treated mice. Only sections that were above the detection limit are shown. 
(c–f) Photomicrographs showing direct GFP fluorescence in mouse brains following injection of mMSCs transduced by FVV:PGK-GFP. Nuclei, stained 
with DAPI, are shown in blue. (c) Right lateral ventricle immediately postinjection; (d) Choroid plexus 45-days postinjection; (e) parenchyma showing 
needle track, 45-days postinjection; (f) glomerular layer of olfactory bulb, 45-days postinjection.
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CPE was observed by microscopy at this high MOI (Figure 7b,c). 
The average time between passages (one-fifth cells reseeded at 
each passage) for transduced and untransduced hMSCs was 4 days 
between each passage until the 7th post-transduction, where the 
time taken between passages doubled as cells putatively entered 
senescence. Transduced hMSCs retained normal osteogenic differ-
entiation potential when tested at 6 passages post-transduction (not 
shown). Therefore, FVV transduction did not affect proliferation or 
function of hMSCs when assessed by these measures.
Flow cytometry was performed for hMSCs transduced at MOIs 
of 1 and 100 with both FVV:PGK-GFP and FVV:EFS-GFP fol-
lowing each passage, until the 10th post-transduction, to monitor 
the percent of GFP expressing cells and their MFI (Figure  7d,e, 
respectively). During cell expansion, until growth slowed, neither 
the percent of hMSCs expressing GFP nor their MFI changed for 
hMSCs transduced with FVV:PGK-GFP or FVV:EFS-GFP at MOI 
1 or 100. Both promoters exerted similar activity. At low MOI, there 
was variation in transduction efficiency of hMSCs from different 
donors, but this became unapparent at high MOI. Following the 
putative entering of senescence, the percent of hMSCs expressing 
GFP reduced at a MOI of 1 from ~7% presenescence to less than 1% 
at the 9th passage post-transduction with FVV:EFS-GFP. A reduc-
tion was also observed for hMSCs transduced at low MOI with 
FVV:PGK-GFP. At high MOI, the percent of GFP-expressing cells 
in FVV:PGK-GFP-transduced hMSCs were unaffected by putative 
senescence, although the MFI became more variable between 
hMSCs from different donors. For just one of the three hMSCs 
transduced with FVV:EFS-GFP at high MOI, the percentage 
expressing GFP dropped from over 95% presenescence to 50.1% 
at the 8th passage post-transduction, resulting in the reduction in 
the average GFP expressing cells transduced with this vector. These 
data show that, at least presenescence, either of the tested FVVs are 
highly suited for high and stable transgene expression.
DISCUSSION
All previous reports on FVVs have used the PFV envelope despite 
its toxicity to cells at high MOI. The SFVmac Env is less toxic since, 
in contrast to PFV Env, it only has significant fusion activity at low 
pH,41 thus preventing fusion at the cell membrane. The PFV Env has 
extremely broad tropism, with only a single zebrafish cell line (Pac2) 
found to be resistant to PFV infection.44 If the SFVmac Env permits 
equally broad tropism, its lack of toxicity would be advantageous. 
We have shown that for mMSCs, the SFVmac Env not only allows 
FVV use at high MOI without inducing syncytia, but unexpectedly 
enables higher transduction efficiencies to be achieved. Making this 
simple change may also benefit FVV transduction of other cell types.
We compared the activity of two constitutive cellular pro-
moters, EFS and PGK, in mMSCs and hMSCs over 10 passages. 
Unexpectedly, the promoter affected the observed transduction 
efficiency in mMSCs. Since our measure of transduction efficiency 
Figure 7 Human MSCs can be efficiently and stably transduced by foamy virus vector (FVV). (a) hMSCs from three donors were transduced with 
FVV:PGK-GFP (white) or FVV:EFS-GFP (black) at the multiplicity of infection (MOIs) indicated on the x-axis and the percentage of GFP expressing cells 
was determined by flow cytometry 1 passage post-transduction. The same vectors, but using the PFV Env, were tested at MOI 50 (brick-patterned 
bars). (b,c) Photomicrographs of hMSCs 3 days post-transduction (no prior passages post-transduction) with FVV:PGK-GFP at a MOI of 100 show-
ing normal cell morphology (b) and GFP fluorescence (c). (d,e) Each time >80% confluence was reached, 1/5th of the hMSCs transduced at MOI 1 
(squares) and MOI 100 (circles) were reseeded until 10 passages post-transduction. At each passage, the percentage of GFP expressing cells (f) and 
their median fluorescence intensity (g) was determined by flow cytometry. All panels show the mean + SD of data from biological triplicates. Asterisks 
in the x-axis labels indicates passages where cultures growth had slowed down, putatively entering senescence (7–10 post-transduction).
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depends on detectable GFP expression in each transduced cell, 
this result is likely caused by the absence of expression in some 
(FVV:EFS-GFP) transduced cells. This may be due to a combina-
tion of the unique integration site selection and/or the inherent 
heterogeneity within MSC populations. By monitoring expression 
through cell expansion (Figure 3), it becomes apparent that the 
EFS promoter is subjected to putative silencing, as the percent of 
GFP-expressing cells decreased during expansion. In contrast, the 
PGK promoter conferred stable expression which peaked at two 
passages post-transduction. This late peak may be explained by 
the FVV’s dependence on cell division for integration and trans-
gene expression.45 The silencing of EFS may also have played a 
role in reducing transduction rates using this promoter by coun-
teracting the increase in GFP-expressing cells, since transduction 
of mMSCs with FVV:EFS-GFP at low MOI did not show a similar 
peak. Interestingly, neither the expression levels nor the observed 
transduction rates were influenced in hMSCs by promoter choice 
(Figure  7), indicating different activities of these housekeeping 
genes between the species of MSCs tested.
Using the lysosomal storage diseases as a proposed tar-
get, we showed that ARSA overexpression by FVVs in mMSCs 
results in strong enzyme activity with a significant amount being 
secreted. This secreted enzyme was appropriately processed since 
it could be used by ARSA deficient cells to clear stored substrate. 
Furthermore, we have shown that mMSC engraftment in the CNS 
is not affected by FVV transduction and in vivo transgene expres-
sion is maintained for at least 45 days. Our long-term engraft-
ment levels and distribution were consistent with published 
results by an independent group using unmodified mMSCs.43 
Lack of a specific marker to identify MSCs in vivo prevents us 
from determining whether the GFP-expressing (MSC-derived) 
cells have maintained MSC identity or not. However, for the pro-
posed use of MSCs as cellular vectors, long-term survival and 
transgene expression is more important than their final identity. 
Thus, the long-term engraftment and FVV-mediated transgene 
expression in vivo that we demonstrate underpins proposals to 
use an MSC-based gene therapy approach for the treatment of 
lysosomal storage diseases affecting the CNS.
Our work has achieved both high and stable transduction effi-
ciency in both mMSCs and hMSCs, allowing the same vector to 
be employed for preclinical and clinical applications. Importantly, 
FVV transduction is not enhanced by polybrene,46 shown to affect 
hMSC proliferation capacity.47 No additives were used to achieve 
high transduction efficiency with FVV. Although high transduc-
tion efficiency in hMSCs has been reported for lentiviral vec-
tors,31,48–50 these included viral promoters/enhancers. Even with a 
viral promoter driving transgene expression, a SIN lentiviral vec-
tor required three rounds of transduction to get 92% efficiency in 
hMSCs.50 Given that viral promoters in a retroviral context have 
been strongly linked to oncogenesis in other cell types,27,30,51 these 
vector designs are unlikely to be approved for clinical use. The 
vector we describe in this paper does not use viral promoters and, 
thus, has stronger clinical prospects.
In addition to our vector being devoid of viral promoters, FVVs 
have innate properties that make them favorable for gene therapy, 
including a potent transcriptional terminator that prevents tran-
scriptional read-through,52 an integration site bias that does not 
favor active genes or their regulatory regions53,54 and being derived 
from a nonhuman apathogenic virus.55 Unfortunately, directly test-
ing our vector’s safety in MSCs is challenging. No transformation 
assays exist for hMSCs which senesce in vitro following long-term 
culture, while mMSCs undergo a pretransformation stage when 
cultured at ambient oxygen levels in vitro, making them unsuitable 
for such analysis. However, we monitored GFP expression during 
significant in vitro expansion yet saw no indication of clonal domi-
nance, since the MFI and the percentage of GFP-expressing cells 
were stable in FVV:PGK-GFP-transduced cells (Figures 3 and 7). 
Moreover, hMSCs became senescent at the same passage num-
ber in transduced and untransduced cells, indicating that a sub-
population was not transformed. Nevertheless, without sensitive 
transformation assays available for MSCs, we are unable to draw 
conclusions on the relative safety of our vector in MSCs. Integration 
site analysis and testing for oncogenic potential in NOD SCID mice 
may be appropriate experiments to be carried out prior to clinical 
translation.
In conclusion, we have developed a potentially safe integrating 
vector that is highly efficient in both mouse and human MSCs. 
For both species of MSC, over 95% express transgene stably for 
at least 10 passages after transduction. All future combined gene 
and MSC therapies should take advantage of the FVV described 
in this work.
MATERIALS AND METHODS
Cell isolation and culture. All cells were cultured under sterile conditions at 
5% CO2 and 37 °C in a humidified incubator. The adherent human embryonic 
kidney and human fibrosarcoma cell lines; HEK-293T56 and HT1080 (ref. 57), 
were cultured in Dulbecco’s Modified Eagle’s medium containing 10% FBS. 
mMSCs were isolated from the bone marrow of 4–6-week-old male C57BL/6 
mice. Bone marrow was flushed from the femurs and tibias of three mice, 
pooled and cultured using the Mesencult Mouse Proliferation kit by StemCell 
Technologies (Cambridge, UK), according to the manufacturer’s recom-
mended protocol with the exception that dissociation was performed using 
TrypLE Express (ThermoFisher Scientific, Hemel Hempstead, Paisley, UK) .
Clinical-grade human bone marrow MSCs were produced in accordance 
of the Regulation (EC) No 1394/2007 of the European Parliament and of the 
Council on advanced therapy medicinal products and amending Directive 
2001/83/EC and Regulation (EC) No 726/2004. For isolation, 2 ml of bone 
marrow aspirate was collected from the iliac crests of healthy donors into 100 
µl preservative-free heparin. Within 24 hours, cells were seeded at a density 
of 15–40,000 cells per cm2 in alpha minimal essential medium containing 
antibiotics and 10% FBS. After 3 days, nonadherent cells were discarded and 
adherent cells cultured until confluence. Cells were maintained using alpha 
minimal essential medium containing 5% human platelet lysate (Stemulate 
PL-NH from Cook Regentec, Limerick, Ireland). When cells reached over 
90% confluence they were dissociated using TrypLE express and reseeded 
at a density of 4,000 per cm2. All hMSCs were tested for surface marker 
expression by flow cytometry and satisfied the recommended minimal 
criteria.58 Over 95% were positive for CD105, CD73, and CD90 expression 
while less than 2% were positive for the negative markers CD45, CD34, 
CD3, CD14, CD19, and HLA-DR.
FVV production. Generation of transfer vector constructs is described in the 
Supplementary Materials and Methods. FVVs were produced in HEK-
293T cells transfected with a 4-plasmid system using PEImax (Park Scientific 
Ltd., Northampton, UK) at a ratio of 3:1 PEI:DNA. The 4-plasmid system 
comprised of one of the pDΦ- transfer plasmids, pcoPG4 (encoding PFV 
Gag), pcoPPwt (encoding PFV pol), and either pcoPE or pcoSE (encoding 
PFV or SFVmac Env, respectively) in the ratio 52:13:6:4, respectively. Plasmids 
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pcoPG4, pcoPPwt and pcoPE have been described previously.59 In a typi-
cal transfection, 5 × 106 HEK-293T cells were seeded per 55 cm2 round cul-
ture dish. The next day, cells were transfected with 15 µg of DNA. Following 
transfection, published protocols for FVV collection, concentration, and 
storage60 were followed.
FVV transduction and titration. For HT1080 cell transduction, 104 cells 
were seeded per cm2 surface area. After 16–24 hours, FVV was added. After 
a further 16–24 hours, medium was replaced. For vectors expressing GFP, 
cells were collected at confluence and the percent of GFP expressing cells 
(using a vector dilution that gave between 1 and 15% GFP expressing cells) 
was determined by flow cytometry. The titer was determined by multiplying 
the proportion of GFP expressing cells by the number of cells at the time 
of vector addition. For ARSA-encoding vectors, qPCR analysis determined 
the FVV DNA content 1 passage post-transduction in transduced HT1080 
cells relative to that of cells transduced with GFP vector of known titer. 
For this, the primers 203-F (AGATTGTACGGGAGCTCTTCAC), 203-R 
(CAGAAAGCATTGCAATCACC) and dual-labeled probe 203-P (FAM-
TACTCGCTGCGTCGAGAGTGTACGA-BHQ-1), which target the FVV 
LTR, were employed. FVV DNA content was normalized to the albumin 
gene using published primers and probe.61
To transduce mMSCs, 2,500 cells were seeded per cm2 in the presence of 
FVV. The cells and vector were centrifuged at 1,200g for 90 minutes at 30 °C 
then cultured normally. After 16–24 hours, medium was replaced. For hMSCs, 
4,000 cells were seeded per cm2. After 16–24 hours, FVV was added and the 
cultures centrifuged as for mMSCs. Medium was replaced after 5–8 hours.
Flow cytometry. To assess the percentage of GFP expressing cells and their 
MFI, at least 10,000 single cells were acquired using a Beckton Dickinson 
LSRII. Single cells were selected using forward and side scatter param-
eters. Untransduced cells served as a negative control to set the gates in the 
488–530/30 channel to determine the percentage of GFP-expressing cells. 
For mMSCs, which exhibited strong autofluorescence, the GFP signal in the 
488–530/30 channel was plotted against the signal in the 488–610/20 chan-
nel. This strategy distinguished between GFP (stronger in 488–530/30 than 
488–610/20) and autofluorescence (similar in both channels). Example plots 
are shown in Supplementary Figure S1. The MFI was calculated by subtract-
ing the median signal intensity of the GFP-negative population from that of 
the GFP-positive population. Surface marker expression analysis for mMSCs 
was carried out using the Mouse Mesenchymal Stem Cell Marker Antibody 
Panel (R&D systems, UK) according to the manufacturer’s recommended 
protocol. Data were acquired using a Beckton Dickinson LSRFortessa. Data 
analysis was performed using FlowJo v10.1 (FlowJo LLC, Ashland, Oregon).
Functional assays. To quantify intracellular ARSA activity, cells were 
collected 5 days after reaching confluence and lysed on ice in 20 mmol/l 
Tris-HCl, pH 8.0, 137 mmol/l NaCl, 1% Triton X-100, and 2 mmol/l 
ethylenediaminetetraacetic acid. Lysates were cleared by centrifugation 
at 16,000g and supernatants collected. Protein concentration was deter-
mined using the DC protein assay (Bio-Rad, laboratories Ltd., Hemel 
Hempstead UK). The ARSA assay was performed as previously described42 
using between 1 and 2 µg protein per reaction. To determine ARSA activ-
ity in cell-culture medium, mMSCs (two passages post-transduction) were 
grown to confluence and complete medium change was performed. After 
5 days, the medium was collected and filtered through a 0.45 µm cellulose 
acetate syringe filter and stored at −20 °C until use. For each reaction, 40 µl 
medium was added. All reactions were performed in triplicate or quadru-
plicate in a 96-well microtiter plate.
BODIPY-sulphatide was produced using Lysosulphatide (Matreya, 
State College, Pennsylvania), BODIPY FL C16 (Life Technologies, 
Mississauga, Canada) and dicyclohexylcarbodiimide (Sigma-Aldrich, 
Ontario, Canada) as previously described.62 Patient fibroblasts (MLD or 
healthy controls) were grown to 75% confluence and BODIPY-sulphatide 
was added to a final concentration of 6.7 mmol/l. After 24 hours, cells 
were rinsed twice with PBS and diluted MSC cell-culture supernatant 
added. Cells were collected for high-performance liquid chromatography 
analysis after a further 24 hours. BODIPY-lactosylceramide (synthesized 
as described for BODIPY-sulphatide) was added as a recovery standard 
and lipids were extracted using chloroform and methanol as described.63 
Chromatographic separations were performed using a Luna C18 column 
(Phenomenex; Torrance, California). The mobile phase consisted of solvent 
A: methanol:water (1:1; v/v) and solvent B: tetrahydrofuran:methanol (4:1; 
v/v). The flow rate was 1 ml/minute. When eluting the column, the mobile 
phase was increased from 40% solvent B to 100% solvent B in 20 minutes, 
held at 100% solvent B for 10 minutes, then decreased back to 40% solvent 
B and held for 10 minutes. The fluorescence detector was set with an 
excitation wavelength of 502 nm and emission wavelength of 530 nm.
The differentiation potential of mMSCs into osteocytes, chondrocytes 
and adipocytes was tested using StemPro Osteogenesis Differentiation Kit, 
StemPro Chondrogenesis Kit (both ThermoFisher Scientific) or MesenCult 
Adipogenic Stimulatory Supplements, mouse (Stemcell technologies), 
respectively. For hMSCs, osteogenic differentiation was tested as for 
mMSCs. Manufacturers’ protocols were followed in all instances. 
Differentiation was confirmed by staining with Alizarin Red, Alcian Blue 
or Oil Red O (all from Sigma-Aldrich, Dorset, UK), respectively.
Stereotaxic injections and tissue processing. ARSA-/- mice, which contain a 
large deletion in the ARSA gene,64  had previously been bred onto a C57BL/6 
background at Western University Ontario, Canada. Procedures were car-
ried out in compliance with the guidelines set by the Canadian Council 
for Animal Care. Stereotaxic injections were carried out as previously 
described.65 Following euthanasia, brains were collected and submerged in 
RNAlater (Qiagen, Ontario, Canada), then frozen at −80 °C. Brains were 
either sectioned using a cryostat for microscopy or cut into blocks for 
genomic DNA extraction. Genomic DNA was extracted using the QIAamp 
DNA mini kit (Qiagen, Manchester, UK). The amount of male DNA pres-
ent in female brains was determined by qPCR according to published pro-
tocols.43 The standard curve was generated by adding genomic DNA from 
mMSCs to genomic DNA extracted from female ARSA-/- mouse brains.
Microscopy. Photomicrographs of tissue sections were acquired using with 
the Openlab imaging software (Perkin Elmer, Ontario, Canada) connected 
to an inverted fluorescence Leica DM IRB microscope (Leica Microsystems, 
Ontario, Canada). Fluorescence and light microscopy of cells in vitro was 
performed using a Nikon Eclipse TE-2000s and images were captured using 
the Nikon ACT-1 software (Nikon, Kingston upon Thames, UK).
Statistical analyses. Graphing and statistical analyses were carried out using 
GraphPad Prism version 6.07 (Graphpad software, San Diego, California). 
Asterisks denote the P value from statistical tests (detailed in Figure legends) 
where P < 0.05*, P < 0.01**, P < 0.001***.
SUPPLEMENTARY MATERIAL
Figure S1. Flow cytometry to determine percent of GFP expressing 
mMSCs.
Materials and  Methods
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